See more : Sino Vision Worldwide Holdings Limited (8086.HK) Income Statement Analysis – Financial Results
Complete financial analysis of TerrAscend Corp. (TRSSF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of TerrAscend Corp., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Coelacanth Energy Inc. (CEIEF) Income Statement Analysis – Financial Results
- Bellicum Pharmaceuticals, Inc. (BLCM) Income Statement Analysis – Financial Results
- Austevoll Seafood ASA (ASTVF) Income Statement Analysis – Financial Results
- Jimoto Holdings, Inc. (7161.T) Income Statement Analysis – Financial Results
- Vendetta Mining Corp. (VTT.V) Income Statement Analysis – Financial Results
TerrAscend Corp. (TRSSF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.terrascend.com
About TerrAscend Corp.
TerrAscend Corp. cultivates, processes, and sells medical and adult use cannabis in Canada and the United States. It produces and distributes hemp-derived wellness products to retail locations; and manufactures cannabis infused artisan edibles. The company also operates three retail dispensaries under the Apothecarium brand name in California and Pennsylvania. In addition, it owns various synergistic under Gage Cannabis, Ilera Healthcare, Kind Tree, Prism, State Flower, Valhalla Confections, and Arise Bioscience Inc. brands. As of July 26, 2022, the company operated 27 dispensaries, including 3 Cookies dispensaries in Michigan and 1 in Toronto. TerrAscend Corp. was incorporated in 2017 and is headquartered in Mississauga, Canada.
Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
---|---|---|---|---|---|---|---|---|
Revenue | 317.33M | 322.64M | 243.49M | 198.32M | 84.87M | 6.83M | 0.00 | 0.00 |
Cost of Revenue | 157.63M | 203.07M | 109.38M | 171.98M | 87.52M | 10.17M | 381.32K | 0.00 |
Gross Profit | 159.70M | 119.57M | 134.11M | 26.34M | -2.65M | -3.34M | -381.32K | 0.00 |
Gross Profit Ratio | 50.33% | 37.06% | 55.08% | 13.28% | -3.12% | -48.96% | 0.00% | 0.00% |
Research & Development | 0.00 | 0.00 | 0.00 | 426.00K | 709.00K | 141.00K | 0.00 | 0.00 |
General & Administrative | 100.35M | 101.22M | 71.85M | 57.01M | 0.00 | 0.00 | 0.00 | 0.00 |
Selling & Marketing | 9.66M | 10.32M | 1.86M | 1.67M | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A | 110.01M | 150.48M | 94.16M | 75.17M | 61.68M | 24.67M | 6.27M | 866.94K |
Other Expenses | 72.69M | 206.00K | 230.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating Expenses | 182.69M | 150.48M | 94.16M | 75.60M | 62.39M | 24.81M | 6.27M | 866.94K |
Cost & Expenses | 340.32M | 353.55M | 203.54M | 247.58M | 149.91M | 34.98M | 6.66M | 866.94K |
Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 640.18K | 36.28K | 9.00 |
Interest Expense | 35.11M | 39.06M | 24.99M | 7.03M | 4.09M | 0.00 | 0.00 | 0.00 |
Depreciation & Amortization | 22.70M | 32.03M | 17.38M | 16.57M | 7.32M | 921.00K | 244.08K | 0.00 |
EBITDA | -1.03M | -320.94M | 104.54M | -96.45M | -204.22M | -20.52M | -6.56M | -866.94K |
EBITDA Ratio | -0.32% | 0.35% | 23.54% | -16.48% | -68.01% | -398.97% | 0.00% | 0.00% |
Operating Income | -23.00M | -30.91M | 39.95M | -49.26M | -65.04M | -28.16M | -6.66M | -866.94K |
Operating Income Ratio | -7.25% | -9.58% | 16.41% | -24.84% | -76.63% | -412.47% | 0.00% | 0.00% |
Total Other Income/Expenses | -35.84M | -279.28M | 15.88M | -77.21M | -152.29M | 6.72M | -149.23K | -244.00 |
Income Before Tax | -58.83M | -403.82M | 55.83M | -126.47M | -217.33M | -21.44M | -6.81M | -867.18K |
Income Before Tax Ratio | -18.54% | -125.16% | 22.93% | -63.77% | -256.08% | -314.09% | 0.00% | 0.00% |
Income Tax Expense | 23.45M | -14.04M | 36.20M | 27.87M | 1.62M | 704.00K | -3.00 | 0.00 |
Net Income | -91.10M | -429.49M | 3.90M | -155.12M | -215.79M | -22.03M | -6.81M | -867.18K |
Net Income Ratio | -28.71% | -133.12% | 1.60% | -78.22% | -254.26% | -322.71% | 0.00% | 0.00% |
EPS | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
EPS Diluted | -0.33 | -1.76 | 0.02 | -1.04 | -2.17 | -0.24 | -0.18 | -0.03 |
Weighted Avg Shares Out | 279.29M | 244.35M | 181.06M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
Weighted Avg Shares Out (Dil) | 279.29M | 244.35M | 208.71M | 149.74M | 99.59M | 90.98M | 37.63M | 29.24M |
TerrAscend Completes $140 Million Debt Financing
TerrAscend to Host Second Quarter 2024 Earnings Conference Call
TerrAscend Announces Results of Annual General Meeting
TerrAscend Celebrates Opening of The Apothecarium Nottingham, Maryland Dispensary
Cannabis Stocks Spike Following Reports Marijuana Will Be Reclassified As Less Dangerous Drug
4/20 2024: Cannabis investors have much to celebrate this year
Cannabis stocks struggle as Canada marks five years of legal recreational use
Cannabis MSO shares rise with marijuana banking reform poised to win Senate Committee's approval
Cannabis MSO winning streak expected to continue as lawmakers vote on SAFE Banking Act
3 Top Pot Stocks to Buy Right Now
Source: https://incomestatements.info
Category: Stock Reports